CTRI/2017/12/010897招募中3 期
Assessing the efficacy of Rituximab (anti CD 20 antibody) added to standard chemotherapy versus standard chemotherapy alone in achieving lower minimal residual disease after induction phase of chemotherapy in CD 20 positive children with Acute Lymphoblastic Leukemia: A pilot study
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Diagnosis of B Cell Acute Lymphoblastic Leukemia
- •2.CD 20 expression in >20 % of blast cells
- •3.Willing to consent for the study
排除标准
- •1.Recieved previous treatment
研究者
相似试验
撤回
2 期
Rituximab Treatment of Focal Segmental GlomerulosclerosisFocal Segmental Glomerulosclerosis (FSGS)NCT00550342National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)10
终止
1 期
Rituximab in Metastatic MelanomaMetastatic MelanomaNCT01032122Medical University of Vienna9
已完成
不适用
The safety and efficacy of anti-CD20 therapy (rituximab) in systemic sclerosisSystemic sclerosisISRCTN77554566Catholic University of the Sacred Heart (Italy)20
撤回
不适用
Assessing Response to Treatment in Non-Hodgkin's Lymphoma Patients Using 64Cu-DOTA-Rituximab PET/CTNon-Hodgkin's LymphomaNCT01598558Sanjiv Sam Gambhir
已完成
1 期
Initial Study of Rituximab to Treat Primary Biliary CirrhosisPrimary Biliary CirrhosisNCT00364819University of California, Davis6